home / stock / aadi / aadi quote
Last: | $1.49 |
---|---|
Change Percent: | 4.2% |
Open: | $1.47 |
Close: | $1.43 |
High: | $1.5053 |
Low: | $1.42 |
Volume: | 33,544 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.49 | $1.47 | $1.43 | $1.5053 | $1.42 | 33,544 | 07-22-2024 |
$1.43 | $1.5209 | $1.43 | $1.55 | $1.42 | 258,770 | 07-19-2024 |
$1.53 | $1.57 | $1.53 | $1.64 | $1.515 | 79,821 | 07-18-2024 |
$1.57 | $1.65 | $1.57 | $1.689 | $1.555 | 105,452 | 07-17-2024 |
$1.66 | $1.5 | $1.66 | $1.67 | $1.5 | 168,245 | 07-16-2024 |
$1.49 | $1.61 | $1.49 | $1.61 | $1.46 | 175,600 | 07-15-2024 |
$1.55 | $1.51 | $1.55 | $1.5695 | $1.51 | 100,964 | 07-12-2024 |
$1.5 | $1.43 | $1.5 | $1.55 | $1.43 | 202,407 | 07-11-2024 |
$1.43 | $1.42 | $1.43 | $1.44 | $1.39 | 82,976 | 07-10-2024 |
$1.39 | $1.37 | $1.39 | $1.41 | $1.36 | 122,934 | 07-09-2024 |
$1.37 | $1.34 | $1.37 | $1.41 | $1.34 | 178,420 | 07-08-2024 |
$1.33 | $1.4 | $1.33 | $1.42 | $1.3201 | 370,877 | 07-05-2024 |
$1.4 | $1.35 | $1.4 | $1.41 | $1.34 | 215,857 | 07-04-2024 |
$1.4 | $1.35 | $1.4 | $1.41 | $1.34 | 215,857 | 07-03-2024 |
$1.32 | $1.42 | $1.32 | $1.4314 | $1.28 | 528,614 | 07-02-2024 |
$1.42 | $1.48 | $1.42 | $1.53 | $1.42 | 273,607 | 07-01-2024 |
$1.46 | $1.62 | $1.46 | $1.66 | $1.46 | 2,405,440 | 06-28-2024 |
$1.63 | $1.62 | $1.63 | $1.64 | $1.59 | 193,139 | 06-27-2024 |
$1.6 | $1.7 | $1.6 | $1.7 | $1.56 | 208,723 | 06-26-2024 |
$1.7 | $1.76 | $1.7 | $1.76 | $1.69 | 142,813 | 06-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Aadi Bioscience to Participate in the Jefferies Healthcare Conference PR Newswire LOS ANGELES , May 29, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapi...
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhi...